When, if ever, would you consider using docetaxel cisplatin 5-FU for first-line metastatic anal cancer?  

In first-line metastatic anal cancer the interAAct study leads us to prefer carboplatin and paclitaxel over cisplatin and 5FU given the lack of difference in ORR with less toxicity. However, given the results of the DCF regimen via the Epitopes-HPV02 study, would you consider using DCF in the first line rather than carboplatin paclitaxel?